Evidence map›Paper›PMID 42883776›Full record

ArticleInternational journal of molecular sciences2026

Berberine Prevents and Reverses Gastric Spasmolytic Polypeptide-Expressing Metaplasia by Modulating M2 Macrophage Polarization.

Jia-Le Li, Shi-Yi Ge, Xing-Xing Zhou, Rong Yan, Ke-Xin Lin, Si-Ran Wu, Xiao-Dong Qu, Na Wang, Jian Wu, Yong-Quan Shi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jia-Le LiState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.
Shi-Yi GeState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.ORCID 0009-0004-2332-3643
Xing-Xing ZhouState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.
Rong YanState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.ORCID 0009-0001-5271-8431
Ke-Xin LinState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.
Si-Ran WuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.
Xiao-Dong QuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.
Na WangState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.ORCID 0000-0003-0789-2681
Jian WuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.
Yong-Quan ShiState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Department of Gastroenterology & Hepatology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.

Funding

Health Commission of Shaanxi Province No. 2024TD-06National Center for Chronic and Noncommunicable Disease Control and Prevention No. 2025ZD0545301National Natural Science Foundation of China No. 82200567National Natural Science Foundation of China No. 82403890Shaanxi Science and Technology Department 2026SF-YBXM-016
6 · The paper itself

Abstract

Spasmolytic polypeptide-expressing metaplasia (SPEM) is a critical gastric precancerous lesion with no approved pharmacological intervention. Berberine (BBR), a natural isoquinoline alkaloid, exhibits pleiotropic anti-inflammatory and antitumor activities. This study investigated whether berberine prevents and/or reverses tamoxifen-induced SPEM in mice and elucidated the underlying mechanisms. A tamoxifen-induced SPEM mouse model was employed with berberine administered via oral gavage in both preventive and therapeutic regimens. Gastric mucosal pathology was assessed by H&E staining, immunohistochemistry, and immunofluorescence. Transcriptomic profiling, bioinformatic analyses, and single-cell RNA sequencing data integration were performed to identify key molecular targets. Berberine significantly attenuated tamoxifen-induced gastric glandular atrophy, accelerated gland recovery, and reduced the number of TFF2

Indexed as

BerberineMacrophagesMetaplasiaPeptidesAnimalsGastric MucosaIntercellular Signaling Peptides and ProteinsMaleMiceSignal TransductionTamoxifenBerberineIntercellular Signaling Peptides and ProteinsPeptidesspasmolytic polypeptideTamoxifenberberineM2 macrophageS100A6SPEMtamoxifen

Identifiers

PMID42883776
PMCPMC13665500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.